AbbVie Inc. is in talks to acquire mental health therapeutics company Gilgamesh Pharmaceuticals in a deal highlighting ...

AbbVie Inc. (NYSE:ABBV) is one of the top low volatility healthcare stocks to buy now. In a report released on July 22, Vamil ...

The fact that multiple AbbVie Inc. ( NYSE:ABBV ) insiders offloaded a considerable amount of shares over the past ...

AbbVie Inc. (NYSE:ABBV) is one of the best long term low volatility stocks to buy now. On July 10, Morgan Stanley analyst ...

Glenmark, through wholly-owned subsidiary IGI Therapeutics SA, announced an exclusive licensing agreement with AbbVie for ISB ...

Glenmark Pharmaceuticals is set to become net cash positive through its licensing agreement with AbbVie Inc. This move aims ...

AbbVie is expected to post earnings of $2.90 per share for the current quarter, representing a year-over-year change of +3.9%. Over the last 30 days, the Zacks Consensus Estimate has changed +0.4%.

This was the stock's third consecutive day of losses.

AbbVie reported revenues of $14.46 billion in the last reported quarter, representing a year-over-year change of +3.8%. EPS of $3 for the same period compares with $2.95 a year ago.

AbbVie to Buy Cancer Treatment Start-Up AbbVie agreed to pay $5.8 billion to acquire Stemcentrx as it continues its big push into cancer treatment. By Michael J. de la Merced and Andrew Pollack ...

AbbVie Inc. (NYSE: ABBV) is reportedly negotiating the acquisition of Gilgamesh Pharmaceuticals, a privately held mental ...

AbbVie to Buy Cancer Treatment Start-Up AbbVie agreed to pay $5.8 billion to acquire Stemcentrx as it continues its big push into cancer treatment. By Michael J. de la Merced and Andrew Pollack ...